Stock News

Quantum (QTM) Reaches $5.25 After 5.00% Up Move; Last Week NeoGenomics, Inc. (NEO) Analysts

The stock of Quantum Corporation (NYSE:QTM) is a huge mover today! The stock increased 3.35% or $0.17 during the last trading session, reaching $5.25. About 131,336 shares traded. Quantum Corporation (NYSE:QTM) has risen 151.14% since December 11, 2016 and is uptrending. It has outperformed by 134.44% the S&P500.The move comes after 5 months positive chart setup for the $182.04 million company. It was reported on Dec, 11 by Barchart.com. We have $5.51 PT which if reached, will make NYSE:QTM worth $9.10 million more.

Among 11 analysts covering NeoGenomics (NASDAQ:NEO), 9 have Buy rating, 1 Sell and 1 Hold. Therefore 82% are positive. NeoGenomics had 17 analyst reports since September 3, 2015 according to SRatingsIntel. As per Wednesday, November 16, the company rating was downgraded by Axiom Capital. As per Thursday, December 15, the company rating was initiated by Cantor Fitzgerald. The firm has “Neutral” rating by BTIG Research given on Monday, September 11. First Analysis initiated the shares of NEO in report on Tuesday, October 4 with “Overweight” rating. The stock of NeoGenomics, Inc. (NASDAQ:NEO) has “Buy” rating given on Thursday, September 3 by Roth Capital. TH Capital reinitiated the shares of NEO in report on Monday, October 26 with “Buy” rating. On Wednesday, May 11 the stock rating was reinitiated by Roth Capital with “Buy”. BTIG Research downgraded the shares of NEO in report on Wednesday, July 27 to “Neutral” rating. Benchmark initiated NeoGenomics, Inc. (NASDAQ:NEO) rating on Friday, March 11. Benchmark has “Buy” rating and $8 target. The stock of NeoGenomics, Inc. (NASDAQ:NEO) has “Buy” rating given on Friday, May 26 by BTIG Research. See NeoGenomics, Inc. (NASDAQ:NEO) latest ratings:

26/10/2017 Broker: Janney Capital Rating: Buy
11/09/2017 Broker: BTIG Research Old Rating: Buy New Rating: Neutral Downgrade
24/08/2017 Broker: Gabelli Rating: Buy Initiates Coverage On

Among 3 analysts covering Quantum (NYSE:QTM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Quantum has $1200 highest and $1.50 lowest target. $5.17’s average target is -1.52% below currents $5.25 stock price. Quantum had 4 analyst reports since August 25, 2015 according to SRatingsIntel. The stock has “Buy” rating by Roth Capital on Tuesday, August 25. The stock of Quantum Corporation (NYSE:QTM) earned “Buy” rating by Roth Capital on Tuesday, June 27. TH Capital initiated Quantum Corporation (NYSE:QTM) rating on Tuesday, August 25. TH Capital has “Buy” rating and $1.5 target.

Investors sentiment decreased to 0 in 2017 Q2. Its down 0.02, from 0.02 in 2017Q1. It dived, as 52 investors sold Quantum Corporation shares while 2 reduced holdings. 1 funds opened positions while 0 raised stakes. 374,429 shares or 99.63% less from 101.59 million shares in 2017Q1 were reported. S Squared Tech Llc, New York-based fund reported 290,065 shares. Jacobs Levy Equity Mngmt Incorporated invested in 83,394 shares or 0.01% of the stock. Glenmede Na stated it has 0% in Quantum Corporation (NYSE:QTM).

Quantum Corporation provides scale-out storage, archive, and data protection solutions for small businesses and multi-national enterprises in the Americas, Europe, and the Asia Pacific. The company has market cap of $182.04 million. The firm offers StorNext 5 software and hardware that offer file sharing and archiving in purpose-built configurations of metadata controllers, expansion appliances, and disk and archive enabled libraries; Xcellis product, which optimizes workflow and shared access by combining functions into a compact, space, and energy-saving solution; and Lattus Object Storage solutions that enable high volumes of data to be available to extract valuable information. It currently has negative earnings. It also offers StorNext Storage Manager software; and StorNext AEL archives products, which provide near-line archiving with built-in data protection and self-healing capabilities.

Analysts await Quantum Corporation (NYSE:QTM) to report earnings on January, 24. They expect $0.22 earnings per share, up 37.50% or $0.06 from last year’s $0.16 per share. QTM’s profit will be $7.63 million for 5.97 P/E if the $0.22 EPS becomes a reality. After $-0.19 actual earnings per share reported by Quantum Corporation for the previous quarter, Wall Street now forecasts -215.79% EPS growth.

Investors sentiment increased to 1.28 in Q2 2017. Its up 0.10, from 1.18 in 2017Q1. It is positive, as 19 investors sold NeoGenomics, Inc. shares while 32 reduced holdings. 17 funds opened positions while 43 raised stakes. 60.13 million shares or 3.48% more from 58.11 million shares in 2017Q1 were reported. Next Century Growth Ltd Liability Com reported 2.54 million shares or 2.18% of all its holdings. Us Fincl Bank De has 1,635 shares. Svcs Automobile Association reported 0.01% stake. Citadel Advsr Limited Liability holds 0% or 287,196 shares. Bard Associate has invested 1.08% in NeoGenomics, Inc. (NASDAQ:NEO). Perkins Cap holds 3.07% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO) for 308,800 shares. Pennsylvania-based Emerald Advisers Pa has invested 0.47% in NeoGenomics, Inc. (NASDAQ:NEO). Florida-based Finemark State Bank & has invested 0.26% in NeoGenomics, Inc. (NASDAQ:NEO). Wells Fargo & Mn invested in 64,033 shares. Bnp Paribas Arbitrage Sa, New York-based fund reported 5,776 shares. Vanguard Group Inc Inc reported 2.72 million shares. Royal Bank & Trust Of Canada owns 192 shares. Scholtz Ltd has 1.7% invested in NeoGenomics, Inc. (NASDAQ:NEO) for 219,500 shares. Parametric Portfolio Associate Ltd invested in 262,128 shares. Icon Advisers Incorporated Com has 57,649 shares.

NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company has market cap of $741.38 million. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. It currently has negative earnings. The firm also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clientsÂ’ oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services.

The stock increased 0.44% or $0.04 during the last trading session, reaching $9.22. About 202,831 shares traded. NeoGenomics, Inc. (NASDAQ:NEO) has declined 13.46% since December 11, 2016 and is downtrending. It has underperformed by 30.16% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *